Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Hidekazu Kondo

Hasama Campus - Faculty of Medicine, Oita University, Yufu City (Japan)

6 More presentations in this session

Presentation thumbnail

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Doctor S. Park (Illkirch, FR)

Abstract Slides

Presentation thumbnail

Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Doctor C. Parco (Ibbenbueren, DE)

Presentation thumbnail

Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Mr J. Ghouse (Copenhagen, DK)

Presentation thumbnail

Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Professor D. McGuire (Dallas, US)

Presentation thumbnail

The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis

Professor C. Desouza (Omaha, US)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting

Congress Presentation

Hypertension and glucose

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources